Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing

Valeant Pharmaceuticals Intl (NYSE: VRX)

$10.75 USD -$0.11 (-1.01%)
Last Price $10.75
Net Change $-0.11 (-1.01%)
Bid $0
Ask Price $0
Open Price $10.83
Previous Close Price $10.86
High Price $10.95
Low Price $10.7
Number of Trades 26,096
Volume 8,928,400
Fifty Two Week High $38.5 (2016-05-03)
Fifty Two Week Low $10.35 (2017-03-21)
Average Daily Volume 19,180,152
Share Outstanding 347,840 Shares
Total Dividend Payout 0/yr
Dividend Yield 0%
1st Quarter Earnings $1.26 (2017-02-28)
2nd Quarter Earnings $1.55 (2016-11-08)
3nd Quarter Earnings $1.4 (2016-08-09)
4th Quarter Earnings $1.27 (2016-06-07)
PE Ratio $1.98
EPS Growth $-27.26
Recent Earnings $1.26
Annual EPS $5.48
Last Quarter EPS $
Market Capitalization $3.74B
Insider Shareholders % 0.1637%
Annual Revenue $0B
No. Shares Outstanding 347,840
Inst. Shareholder % 57.53%
Annual Net Income $-2.41B
TTM Net Profit Margin $-24.9
1-Year Return -62.75%
3-Year Return -91.67%
5-Year Return -80.31%
5-Year Revenue Growth 292.7%
5-Year Earnings Growth 100.37%
5-Year Dividend Growth 0%
Annual Dividend $0
Annual Dividend Yield 0%
Change in EPS YTD -27.26%
Dividends per Share $1
Stock Split Ratio 2-1
Beta -0.2
Valeant Pharmaceuticals International Inc. is a pharmaceutical company that develops manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant's development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain taribavirin of the treatment of chronic hepatitis C and several dermatology candidates for the treatment of rosacea acne and dermatological fungus. Valeant Pharmaceuticals International Inc. is headquartered in Mississauga Canada.

Today's Valeant Pharmaceuticals Stock Update

There aren't enough hours in the day to get a detailed look at your favorite investments, like Valeant Pharmaceuticals stock. So here's a quick look at VRX's most important numbers right now (for March 25, 2017). To start, let's look at the Valeant Pharmaceuticals stock closing price. Shares ended the day's trading session at $10.75. They dropped 1.01% or $0.11 from the previous day's close. Here's how the current Valeant Pharmaceuticals stock price level compares to recent highs and lows... Valeant Pharmaceuticals is currently trading at a lower price than it was one-year ago, with shares down 65.42% from then.

BREAKING: How a 26(f) Program Can Save Your Retirement

The Valeant Pharmaceuticals stock price 52-week high is $38.50. That was hit on 5/03/2016. The VRX stock 52-week low is $10.35, reached on 3/21/2017. Also important to note - VRX trading volume yesterday was 15,675,200. That's more than Valeant Pharmaceuticals stock's average daily trading volume of 8,928,415. Valeant Pharmaceuticals's market capitalization - the amount of shares outstanding times the share price - is 3,739,280,000. That gives Valeant Pharmaceuticals a mid-size market cap, because it's been 2 billion and 10 billion. As of the start of April 2016, Apple has the biggest market cap of all publicly traded companies.

TRENDING: The Best Stocks to Buy Now

The current P/E (price/earnings) ratio of Valeant Pharmaceuticals stock is 1.95. That's not as high as the March 2016 S&P 500 P/E ratio of about 23. To really gauge if this stock's P/E is high or low, you should compare VRX to other companies in the same industry. The current EPS (earnings per share) of VRX is -6.92. Beta - how closely the stock trades with the overall market, with a beta of 1 meaning it trades in step with the broader index -- for Valeant Pharmaceuticals is -0.20. Valeant Pharmaceuticals stock does not pay a dividend right now. Most income investors look for "dividend stocks" that have a yield of 2% or more, but there are different factors that affect the health of a company's payout. Money Morning gives you Valeant Pharmaceuticals stock news daily. We publish new info on VRX and dozens of other key companies we're watching now, every day, so investors will never miss an opportunity. As always, our content is free.

UP NEXT: These Are the Top 5 Marijuana Stocks to Watch in 2017 - Don't Miss This Sector's Staggering Profit Potential

Click here to read more stories